Pharma Journalist -

With the recent FDA-approvals of Bayer’s Eylea HD 8mg as a durable long-term treatment for Wet AMD and Genentech’s Vabysmo for Retinal Vein Occlusion (RVO), now is the time to unite…
Read More...

AbbVie Inc. and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with…
Read More...

Bristol-Myers Squibb K.K. announced that the company has received manufacturing and marketing approval of the supplemental New Drug Application for an additional indication for Abecma …
Read More...

With Novartis joining the suprachoroidal race with their novel injector and Genentech's re-designed sustained release formulations showing promise for wet AMD, there has never been a…
Read More...

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination…
Read More...

ImmunoGen, Inc. announced that the US Food and Drug Administration (FDA) has filed the supplemental Biologics License Application (sBLA) supporting the conversion of the accelerated…
Read More...

AQEMIA, a pioneering pharmatech company leveraging AI and quantum-inspired physics to accelerate the discovery of small molecule drug candidates with higher probability of success in…
Read More...

On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.…
Read More...

Vanda Pharmaceuticals Inc. (Vanda) announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's New Drug Application (NDA) for tradipitant for the…
Read More...

Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announced closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi.…
Read More...